Orphan drugs and gene therapies – solving the HTA and pricing conundrum

Wed, 2018 / 10 / 10

About the author

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18
On the 1st and 2nd of November, the “Rare Diseases and Orphan Drugs Global Forum 2018” provides stakeholders a platform to get together to work on improving treatment options for rare disease patients. SKC will be attending the forum, which is being held in Belgrade, Serbia this year.

SKC’s managing director Prof. Matthias P. Schönermark, Ph. D., M.D. will hold the opening remarks and a keynote about “Orphan drugs and gene therapies – solving the HTA and pricing conundrum” on the first day of the congress and he will also be co-chairing the forum with Clévio Nóbrega, Assistant Professor at the University of Algarve on that day.

In the light of the wide range of challenges, Prof. Schönermark will present the positions relevant to the approval and reimbursement of gene therapies on national and international levels and he will portray possible strategic options and room for maneuver based on these positions.

SKC is the leading strategy consultancy in the German health care sector. Further insights, resulting from our long-lasting experience and deep network, can be gathered from our White Papers:

BY Prof. Matthias P. Schönermark, M.D., Ph.D., managing director and Karolin Priese, MBA

More information can be found at https://www.rarebase.co.uk/rare-diseases-and-orphan-drugs-global-forum-2018.
to the top